Diabetic RetinopathyPROGRESS10NCT04650165
10-year Progression of Diabetic Retinopathy: Identification of Signs and Surrogate Outcomes
An observational study of Diabetic Retinopathy, run by Association for Innovation and Biomedical Research on Light and Image at 1 site in Portugal.
Trial summary
To characterize both functionally and morphologically initial Diabetic Retinopathy (DR) stages and their progression over a period of 10 years. Read more about this study
- Who is it for?
- Ages 35 to 80 years
- Conditions the study is for
- Diabetic Retinopathy
- How many people
- 119 participants
- Where
- 1 sitePortugal
- Study dates
- 1 Jun 2021to 27 Mar 2024
- How long will I take part?
- 3 Years
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Male and female subjects older than 50 years-old with type 2 Diabetes mellitus and no Diabetic Retinopathy or mild Non-Proliferative Diabetic Retinopathy who have participated in the PROGRESS study (NCT03010397).
Who may be able to join
- Subjects who have participated in the PROGRESS study;
- Subjects capable of understanding the information about the study and to give their informed consent to enter the study.
- Subjects willing and able to comply with the study
Who cannot join
- Inadequate ocular media and/ or pupil dilatation that interfere with fundus examinations
Trial locations and contacts
1 site in 1 country.
Portugal1 site
AIBILI - Association for Innovation and Biomedical Research on Light and Image
Coimbra, 3000-548
About this study
To characterize both functionally and morphologically initial Diabetic Retinopathy (DR) stages and their progression over a period of 10 years.
Read the detailed description
Diabetic retinopathy (DR) is the most frequent complication of diabetes mellitus and the leading cause of legal blindness in active populations of industrialized countries. Progression of DR has been up to now classified according to the ETDRS classification, based on a multicentric study that evaluated the effect of laser photocoagulation on advanced stages of DR. Although appropriate for late stages of DR, it does not grade progression well in the initial stages of the disease. Initial stages of DR require urgent characterization and their evolution should be well defined because some of the lesions are still reversible.
The early stages of DR are characterized by 4 main alterations: microaneurysms (MA) and retinal hemorrhages, represented by red dots in the fundus, blood-retinal barrier breakdown, capillary closure and damage of neuronal and glial cells of the retina. Thus, there are both microvascular changes, with endothelial cell and pericyte damage with thickening of basement membrane, and neuronal changes.
Based on previous studies, progression of DR does not occur at the same rate in all patients. Some never develop vision loss, whereas others rapidly progress to macular edema or neovascularization leading to vision loss. The understanding of the mechanisms that balance in different direction is of outmost importance. The duration of diabetes mellitus and the metabolic control are major risk factors for DR progression, but they are insufficient to explain the great variability observed in patients.
Recent data indicate that MA turnover may be an appropriate indicator of DR progression. Our research group has identified different DR progression phenotypes. Phenotype A is characterized by a low MA turnover, phenotype B characterized by increased thickness and phenotype C with predominant ischemia, with a high MA turnover. These phenotypes were defined based on MA turnover (RetmarkerDR) and on central retinal thickness (RT) measured by Optical Coherence Tomography (OCT) and the model was able to correctly identify eyes at risk of progression. 61,8-76,7% of eyes with an increase RT in the central subfield, inner and/or outer ring allowed a MA formation rate ≥ 2 and/or a MA turnover ≥ 6. More recently, some genetic variants have been linked to the different phenotypes and may explain specific progression patterns.
There is emerging evidence to suggest that retinal neurodegeneration is an early event in the pathogenesis of DR and that it could participate in the development of microvascular abnormalities. The understanding of the underlying mechanisms leading to neurodegeneration and the identification of the mediators between neurodegeneration and microangiopathy is essential.
The Investigators aim to understand the extent of these cell abnormalities in the initial stages of DR and to characterize their progression.
Analysis of retinal thickness using OCT offers non-invasive evaluation of retinal edema and can suggest an appropriate treatment target. The Investigators will use recent and innovative approaches as Spectral domain OCT (SD-OCT) with retinal layers segmentation to study neurodegenerative changes occurring in DR. OCT-Angiography and OCT-Leakage layer by layer analysis will be used for microvasculature and blood retinal barrier assessment.
- Conditions
- Diabetic Retinopathy
- Medical subject headings
- Diabetic Retinopathy
What is being measured
The primary outcome is the main question the study is designed to answer.
Phenotypic classification of DR in a 5-year period
Presence CME (Central Macular Edema) or PDR (Proliferative Diabetic Retinopathy)
Measured: 5 years
DR severity level
Early Treatment Diabetic Retinopathy Study Research Group, grading (7 fields-CFP)
Measured: 5 years
Secondary outcomes (7)
Choroidal thickness analysis
Choroidal thickness assessed by Enhanced Depth Imaging (EDI) SD-OCT
Measured: 5 years
Retinal thickness analysis
Retinal thickness (RT) in central subfield, inner and outer rings, assessed by SD-OCT and using layer-by-layer segmentation
Measured: 5 years
Ellipsoid zone analysis
Degree of integrity of the ellipsoid zone, assessed by SD-OCT
Measured: 5 years
SD- OCT- Angiography analysis
Vessel analysis, assessed by SD-OCT OCT-Angiography
Measured: 5 years
OCT-Leakage analysis
LOR (low optical reflectivity) ratio in central subfield, inner and outer ring for assessment of BRB breakdown, assessed by OCT-Leakage
Measured: 5 years
Retinal thickness quantification
Retinal nerve fiber layer thickness (RNFL) and ganglion cells layer (GCL) + inner plexiform layer thickness (IPL) thickness, assessed by layer-by-layer SD-OCT
Measured: 5 years
mfERG assessement
P1 implicit time and P1 amplitude by ring
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Dec 2020
- Study start1 Jun 2021
- Primary completion27 Mar 2024
- Study completion27 Mar 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Diabetic RetinopathyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 119 participants (actual)
- Target duration
- 3 Years
Sponsor and investigators
- Lead sponsor
- Association for Innovation and Biomedical Research on Light and Image
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Inês P Marques, MD, Principal investigator, AIBILI - Association for Innovation and Biomedical Research on Light and Image
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04650165
- Sponsor's protocol ID
- CEC/011/20
- Acronym
- PROGRESS10
- Status last verified
- Oct 2024
- First submitted
- 25 Nov 2020
- Last updated
- 16 Oct 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 16 Oct 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- 10-year Progression of Diabetic Retinopathy: Identification of Signs and Surrogate Outcomes
- ClinicalTrials.gov ID
- NCT04650165
- Acronym / sponsor ID
- PROGRESS10 / CEC/011/20
- Conditions
- Diabetic Retinopathy
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 119 participants (actual)
- Lead sponsor
- Association for Innovation and Biomedical Research on Light and ImageUniversity, hospital or other
- Study start
- 1 Jun 2021 (actual)
- Primary completion
- 27 Mar 2024 (actual)
- Study completion
- 27 Mar 2024 (actual)
- First posted
- 2 Dec 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To characterize both functionally and morphologically initial Diabetic Retinopathy (DR) stages and their progression over a period of 10 years.
Detailed description
Diabetic retinopathy (DR) is the most frequent complication of diabetes mellitus and the leading cause of legal blindness in active populations of industrialized countries. Progression of DR has been up to now classified according to the ETDRS classification, based on a multicentric study that evaluated the effect of laser photocoagulation on advanced stages of DR. Although appropriate for late stages of DR, it does not grade progression well in the initial stages of the disease. Initial stages of DR require urgent characterization and their evolution should be well defined because some of the lesions are still reversible.
The early stages of DR are characterized by 4 main alterations: microaneurysms (MA) and retinal hemorrhages, represented by red dots in the fundus, blood-retinal barrier breakdown, capillary closure and damage of neuronal and glial cells of the retina. Thus, there are both microvascular changes, with endothelial cell and pericyte damage with thickening of basement membrane, and neuronal changes.
Based on previous studies, progression of DR does not occur at the same rate in all patients. Some never develop vision loss, whereas others rapidly progress to macular edema or neovascularization leading to vision loss. The understanding of the mechanisms that balance in different direction is of outmost importance. The duration of diabetes mellitus and the metabolic control are major risk factors for DR progression, but they are insufficient to explain the great variability observed in patients.
Recent data indicate that MA turnover may be an appropriate indicator of DR progression. Our research group has identified different DR progression phenotypes. Phenotype A is characterized by a low MA turnover, phenotype B characterized by increased thickness and phenotype C with predominant ischemia, with a high MA turnover. These phenotypes were defined based on MA turnover (RetmarkerDR) and on central retinal thickness (RT) measured by Optical Coherence Tomography (OCT) and the model was able to correctly identify eyes at risk of progression. 61,8-76,7% of eyes with an increase RT in the central subfield, inner and/or outer ring allowed a MA formation rate ≥ 2 and/or a MA turnover ≥ 6. More recently, some genetic variants have been linked to the different phenotypes and may explain specific progression patterns.
There is emerging evidence to suggest that retinal neurodegeneration is an early event in the pathogenesis of DR and that it could participate in the development of microvascular abnormalities. The understanding of the underlying mechanisms leading to neurodegeneration and the identification of the mediators between neurodegeneration and microangiopathy is essential.
The Investigators aim to understand the extent of these cell abnormalities in the initial stages of DR and to characterize their progression.
Analysis of retinal thickness using OCT offers non-invasive evaluation of retinal edema and can suggest an appropriate treatment target. The Investigators will use recent and innovative approaches as Spectral domain OCT (SD-OCT) with retinal layers segmentation to study neurodegenerative changes occurring in DR. OCT-Angiography and OCT-Leakage layer by layer analysis will be used for microvasculature and blood retinal barrier assessment.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 3 Years
Who may qualify
- Ages
- 35 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Male and female subjects older than 50 years-old with type 2 Diabetes mellitus and no Diabetic Retinopathy or mild Non-Proliferative Diabetic Retinopathy who have participated in the PROGRESS study (NCT03010397).
Key inclusion criteria (3 listed)
- Subjects who have participated in the PROGRESS study;
- Subjects capable of understanding the information about the study and to give their informed consent to enter the study.
- Subjects willing and able to comply with the study
Key exclusion criteria (1 listed)
- Inadequate ocular media and/ or pupil dilatation that interfere with fundus examinations
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Phenotypic classification of DR in a 5-year period
Time frame: 5 years
Presence CME (Central Macular Edema) or PDR (Proliferative Diabetic Retinopathy)
DR severity level
Time frame: 5 years
Early Treatment Diabetic Retinopathy Study Research Group, grading (7 fields-CFP)
7 secondary outcomes
Choroidal thickness analysis
Time frame: 5 years
Retinal thickness analysis
Time frame: 5 years
Ellipsoid zone analysis
Time frame: 5 years
SD- OCT- Angiography analysis
Time frame: 5 years
OCT-Leakage analysis
Time frame: 5 years
Retinal thickness quantification
Time frame: 5 years
mfERG assessement
Time frame: 5 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Oct 2024.
- Individual participant dataSharing planned: Undecided
Related trials for Diabetic Retinopathy
Recruiting
Implementing AI-based Glaucoma Screening Within Federally Qualified Health Centers
Glaucoma, Ocular Hypertension
Active, not recruitingObservational study
Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)
Diabetic Macular Edema, Neovascular Age-related Macular Degeneration
Active, not recruitingPhase 2
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic Retinopathy
Diabetic Retinopathy, DR
Recruiting
To Investigate the Feasibility and Acceptability of Trained Non-medical Professionals Performing Laser Treatment for Proliferative Diabetic Retinopathy (PDR), and the Potential Impact on Service Capacity. Assess Feasibility of Conducting a Full Trial Comparing Trained ECPs With Ophthalmologists
Proliferative Diabetic Retinopathy (PDR)
RecruitingPhase 2
Oral N-Acetylcysteine on Diabetic Macular Edema
Diabetic Macular Edema (DME)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Inês P Marques, MD principal investigator
AIBILI - Association for Innovation and Biomedical Research on Light and Image
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Diabetic Retinopathy, run by Association for Innovation and Biomedical Research on Light and Image at 1 site in Portugal.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Portugal. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Phenotypic classification of DR in a 5-year period (time frame: 5 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Oct 2024.